

TABLE 91: DOSAGE REGIMENS: COMBINED TREATMENT POPULATION (SUSTAINED VIROLOGIC RESPONSE)

| STUDY/TREATMENT | GENOTYPE 1 OR GENOTYPES 2 TO 6 | | | | | | | | | | | GENO-TYPES 2 TO 6 | | |
|---|--------------------------------|---------------|---------------|-------------|--------------------|-----------------------|-----------------------------------|-----------------------------------|---------------|---------------|--------------|---------------------|--------------|---------------|
| | SOF24 + RBV24 | SIM12 + SOF12 | SOF12 + LDV12 | SOF8 + LDV8 | SOF8 + LDV8 + RBV8 | SOF12 + LDV12 + RBV12 | PAR/RIT12 + OMB12 + DAS12 + RBV12 | PAR/RIT24 + OMB24 + DAS24 + RBV24 | DCV24 + ASU24 | DCV12 + SOF12 | SOF12 + PR12 | SIM12 + PR24-48 RGT | SIM12 + PR48 | SOF12 + RBV12 |
| Included in the NMA (SVR) | | | | | | | | | | | | | | |
| Dieterich et al., 2014 | | | | | | | | | | | | x | x | |
| Gane et al., 2013 ELECTRON | | | | | | | | | | x | | | | x |
| Gane et al., 2014 ELECTRON | | | | | | x | | | | | | | | |
| Jacobson et al., 2013 Fusion | | | | | | | | | | | | | | x |
| Kumada et al., 2014 | | | | | | | | | x | | | | | |
| Lalezari et al. et al., 2015 | | | | | | | x | | | | | | | |
| Lawitz et al., 2014 COSMOS | | x | | | | | | | | | | | | |
| Lawitz et al., 2014 LONESTAR | | | x | x | x | x | | | | | | | | |
| Manns et al., 2014 HALLMARK-DUAL | | | | | | | | | x | | | | | |
| Mizokami et al., 2015 | | | x | | | x | | | | | | | | |
| Molina et al., 2015 PHOTON-2 | x | | | | | | | | | | | | | x |
| Muir et al., 2015 UNITY-2 | | | | | | | | | | | | | | |
| Nelson D. et al., accepted in 2015 ALLY-3 (AI444-218) | | | | | | | | | | x | | | | |
| Omata M et al., 2014 | | | | | | | | | | | | | | x |
| Pearlman et al., 2015 | | x | | | | | | | | | x | | | |
| Poordad et al. et al., 2015 UNITY-1 | | | | | | | | | | | | | | |
| Ruane et al., 2014 | x | | | | | | | | | | | | | x |
| Sulkowski et al., 2014 | x | | | | | | | | | | | | | x |
| Sulkowski et al., 2014 | | | | | | | | | | x | | | | |
| Zeuzem et al., 2014 | x | | | | | | | | | | | | | x |
| Not included in the NMA (SVR) | | | | | | | | | | | | | | |
| Jacobson et al., 2013 POSITRON | | | | | | | | | | | | | | x |
| Poordad et al., 2014 TURQUOISE-II | | | | | | | x | x | | | | | | |
| Lawitz et al., 2015 C-WORTHY | | | | | | | | | | | | | | |
| Sulkowski et al., 2015 C-WORTHY | | | | | | | | | | | | | | |
| Sulkowski et al., 2015 TURQUOISE-I-1a | | | | | | | x | | | | | | | |

ASU = asunaprevir; BEC = beclabuvir; DAS = dasabuvir; DCV = daclatasvir; LDV = ledipasvir; NMA = network meta-analysis; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response.

NOTE: PLEASE REFER TO TREATMENT REGIMEN NOMENCLATURE TABLE FOR DESCRIPTION OF DOSAGES.